Jun 17, 2024 · CHIKV VLP is a virus-like particle (VLP)-based vaccine candidate for active immunization against chikungunya disease. Two Phase 3 clinical trials of CHIKV VLP have been completed, evaluating the vaccine in more than 3,600 individuals aged 12 years and above.

Jun 17, 2024 · CHIKV VLP is an adjuvanted VLP-based vaccine candidate for active immunization against chikungunya disease. Pending regulatory approval, the single-dose vaccine will be made in a pre-filled syringe, designed to ease administration by saving vaccinators' time and reducing the risk of administrative errors.

Aug 6, 2023 · In June 2023, Bavarian Nordic reported positive topline data from a similar Phase 3 study in healthy adults ≥65 years of age (NCT05349617), which demonstrated that CHIKV VLP induced chikungunya neutralizing antibodies in 87% of vaccinees 22 days after a single vaccination and was well-tolerated.

Oct 23, 2024 · CHIKV VLP vaccine clinical program ... Bennett et al. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomized, double-blind, parallel-group, phase 2 trial. Lancet Infect Dis. 2022;22(9):1343-55. ClinicalTrials.gov ID: NCT05065983; 3. ClinicalTrials.gov ID: NCT03992872; 4.

5 days ago · First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets ...

6 days ago · Bavarian Nordic ’s chikungunya vaccine Vimkunya is one step closer to being available in Europe after having secured an European Medicines Agency (EMA) recommendation for a marketing authorisation. If authorised, Vimkunya would be the first vaccine in the EU to protect individuals aged 12 and older against chikungunya, a mosquito-borne disease that leads to fever and joint pain. While most ...

6 days ago · Overview On 30 January 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Vimkunya, a vaccine intended for the prevention of chikungunya disease in individuals aged 12 years and older. The applicant for this medicinal product is Bavarian Nordic A/S. Vimkunya was reviewed ...

3 days ago · Bavarian Nordic is likely just weeks away from bringing the second chikungunya vaccine to the EU, and the first approved for use in adolescents.

Jun 20, 2023 · Danish drugmaker Bavarian Nordic on Tuesday said a chikungunya virus vaccine it’s developing succeeded in a Phase 3 study testing the shot in more than 400 healthy older adults. According to the company, the vaccine met the trial’s primary goals, spurring protective antibodies in nearly 90% of participants three weeks after they received the shot.

Aug 6, 2023 · The results up to day 22 post vaccination showed that CHIKV VLP was highly immunogenic in healthy adolescents and adults, as demonstrated by the strong induction of chikungunya neutralizing...